Synta Will Sing A New Tune As Madrigal

Synta Pharmaceuticals Corp. will sing a new tune as Madrigal Pharmaceuticals Inc. after an all-stock reverse merger that will give Madrigal shareholders a 64% stake in the combined company, which will focus on cardiovascular, metabolic and liver diseases instead of Synta's failed cancer programs.